Table 5.
Short-term outcomes and early recurrence by ENI-Score group.
| Outcome | Low-benefit (n=251) | Intermediate (n=267) | High-benefit (n=220) | P-trend |
|---|---|---|---|---|
| MPR | 26 (10.4) | 102 (38.2) | 174 (79.1) | <0.001 |
| pCR | 3 (1.2) | 32 (12.0) | 77 (35.0) | <0.001 |
| ORR | 84 (33.5) | 178 (66.7) | 193 (87.7) | <0.001 |
| DCR | 210 (83.7) | 252 (94.4) | 218 (99.1) | <0.001 |
| ypN0 | 63 (25.1) | 99 (37.1) | 138 (62.7) | <0.001 |
| R0 resection | 224 (89.2) | 246 (92.1) | 214 (97.3) | 0.001 |
| Any irAE | 61 (24.3) | 74 (27.7) | 60 (27.3) | 0.887 |
| Recurrence ≤12 mo | 59 (23.5) | 26 (9.7) | 18 (8.2) | <0.001 |
Values are n (%). P-trend is from the Cochran–Armitage trend test across ordered ENI-Score groups. irAE, immune-related adverse event; other abbreviations as in Table 1.